Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 103

1.

Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer.

Nakai Y, Tanaka N, Asakawa I, Torimoto K, Miyake M, Anai S, Fujii T, Hasegawa M, Fujimoto K.

J Contemp Brachytherapy. 2019 Oct;11(5):409-416. doi: 10.5114/jcb.2019.88142. Epub 2019 Oct 30.

2.

Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosterone.

Nakai Y, Tanaka N, Asakawa I, Anai S, Miyake M, Morizawa Y, Hori S, Owari T, Fujii T, Yamaki K, Hasegawa M, Fujimoto K.

Jpn J Clin Oncol. 2019 Oct 28. pii: hyz136. doi: 10.1093/jjco/hyz136. [Epub ahead of print]

PMID:
31665354
3.

A Potential Application of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Combined with Photodynamic Diagnosis for the Detection of Bladder Carcinoma in Situ: Toward the Future 'MRI-PDD Fusion TURBT'.

Miyake M, Maesaka F, Marugami N, Miyamoto T, Nakai Y, Ohnishi S, Gotoh D, Owari T, Hori S, Morizawa Y, Itami Y, Inoue T, Anai S, Torimoto K, Fujii T, Shimada K, Tanaka N, Fujimoto K.

Diagnostics (Basel). 2019 Sep 4;9(3). pii: E112. doi: 10.3390/diagnostics9030112.

4.

Urinary nerve growth factor can predict therapeutic efficacy in children with monosymptomatic nocturnal enuresis.

Morizawa Y, Aoki K, Iemura Y, Hori S, Gotoh D, Fukui S, Nakai Y, Miyake M, Torimoto K, Tanaka N, Fujimoto K.

Neurourol Urodyn. 2019 Nov;38(8):2311-2317. doi: 10.1002/nau.24142. Epub 2019 Aug 20.

PMID:
31432572
5.

Evaluation of Preoperative Abdominal Adipose Tissue-, Inflammation-, Muscle Mass-, and Nutritional Status-based Prognostic Markers to Assess Renal Dysfunction in Living Kidney Donors.

Hori S, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Miyake M, Anai S, Torimoto K, Aoki K, Yoneda T, Tanaka N, Yoshida K, Fujimoto K.

Transplant Proc. 2019 Jul - Aug;51(6):1706-1716. doi: 10.1016/j.transproceed.2019.04.057.

PMID:
31399161
6.

Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.

Miyake M, Hori S, Ohnishi S, Toritsuka M, Fujii T, Shimizu T, Owari T, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Anai S, Torimoto K, Tanaka N, Fujimoto K.

Cancer Sci. 2019 Oct;110(10):3315-3327. doi: 10.1111/cas.14158. Epub 2019 Aug 19.

7.

The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions.

Miyake M, Tanaka N, Asakawa I, Owari T, Hori S, Morizawa Y, Nakai Y, Inoue T, Anai S, Torimoto K, Hasegawa M, Fujii T, Konishi N, Fujimoto K.

Prostate Int. 2019 Jun;7(2):47-53. doi: 10.1016/j.prnil.2018.04.005. Epub 2018 May 5.

8.

Clinical Significance of Postoperative Nutritional Status as a Prognostic Factor in Kidney Transplant Recipients.

Hori S, Ichikawa K, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Miyake M, Yoneda T, Tanaka N, Yoshida K, Fujimoto K.

Transplant Proc. 2019 Jul - Aug;51(6):1763-1772. doi: 10.1016/j.transproceed.2019.04.047. Epub 2019 Jun 27.

PMID:
31255359
9.

Clinical Impact of the Increase in Immunosuppressive Cell-Related Gene Expression in Urine Sediment during Intravesical Bacillus Calmette-Guérin.

Miyake M, Hori S, Ohnishi S, Owari T, Iida K, Ohnishi K, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Inoue T, Anai S, Torimoto K, Aoki K, Fujii T, Tanaka N, Fujimoto K.

Diseases. 2019 Jun 18;7(2). pii: E44. doi: 10.3390/diseases7020044.

10.

Evaluation of pro‑ and anti‑tumor effects induced by three colony‑stimulating factors, G‑CSF, GM‑CSF and M‑CSF, in bladder cancer cells: Is G‑CSF a friend of bladder cancer cells?

Hori S, Miyake M, Onishi S, Morizawa Y, Nakai Y, Tatsumi Y, Onishi K, Iida K, Gotoh D, Itami Y, Tanaka N, Fujimoto K.

Int J Oncol. 2019 Jun;54(6):2237-2249. doi: 10.3892/ijo.2019.4772. Epub 2019 Apr 4.

PMID:
31081057
11.

Long-term Changes in Renal Function, Blood Electrolyte Levels, and Nutritional Indices after Radical Cystectomy and Ileal Conduit in Patients with Bladder Cancer.

Miyake M, Owari T, Tomizawa M, Matsui M, Nishibayashi N, Iida K, Onishi K, Hori S, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Inoue T, Anai S, Torimoto K, Aoki K, Tanaka N, Fujimoto K.

Urol J. 2019 May 5;16(2):145-151. doi: 10.22037/uj.v0i0.4531.

12.

Comparison of cancer detection rates by transrectal prostate biopsy for prostate cancer using two different nomograms based on patient's age and prostate volume.

Hori S, Tanaka N, Nakai Y, Morizawa Y, Tatsumi Y, Miyake M, Anai S, Fujii T, Konishi N, Nakagawa Y, Hirao S, Fujimoto K.

Res Rep Urol. 2019 Mar 19;11:61-68. doi: 10.2147/RRU.S193933. eCollection 2019.

13.

Prognostic impact of tumor-infiltrating CD276/Foxp3-positive lymphocytes and associated circulating cytokines in patients undergoing radical nephrectomy for localized renal cell carcinoma.

Iida K, Miyake M, Onishi K, Hori S, Morizawa Y, Gotoh D, Itami Y, Onishi S, Nakai Y, Anai S, Tanaka N, Fujimoto K.

Oncol Lett. 2019 Apr;17(4):4004-4010. doi: 10.3892/ol.2019.10057. Epub 2019 Feb 20.

14.

Clinical benefit of early treatment with bone-modifying agents for preventing skeletal-related events in patients with genitourinary cancer with bone metastasis: A multi-institutional retrospective study.

Owari T, Miyake M, Nakai Y, Hori S, Tomizawa M, Ichikawa K, Shimizu T, Iida K, Samma S, Iemura Y, Momose H, Omori C, Otani T, Kuwada M, Hirao S, Oyama N, Nakagawa Y, Hayashi Y, Tanaka N, Fujimoto K.

Int J Urol. 2019 Jun;26(6):630-637. doi: 10.1111/iju.13939. Epub 2019 Mar 18.

PMID:
30883931
15.

Mycoplasma genitalium Infection and Chronic Inflammation in Human Prostate Cancer: Detection Using Prostatectomy and Needle Biopsy Specimens.

Miyake M, Ohnishi K, Hori S, Nakano A, Nakano R, Yano H, Ohnishi S, Owari T, Morizawa Y, Itami Y, Nakai Y, Inoue T, Anai S, Torimoto K, Tanaka N, Fujii T, Furuya H, Rosser CJ, Fujimoto K.

Cells. 2019 Mar 2;8(3). pii: E212. doi: 10.3390/cells8030212.

16.

The diagnostic utility of retroperitoneoscopic tissue biopsy for unresectable retroperitoneal lesions excluding urogenital cancers.

Miyake M, Fukui S, Gotoh D, Matsumura Y, Samma S, Matsumoto Y, Momose H, Hori S, Watanabe S, Owari T, Morizawa Y, Itami Y, Nakai Y, Inoue T, Anai S, Torimoto K, Aoki K, Tanaka N, Fujimoto K.

World J Surg Oncol. 2019 Feb 18;17(1):35. doi: 10.1186/s12957-019-1581-0.

17.

Effect of bladder distension on arginine vasopressin secretion in rats.

Morizawa Y, Torimoto K, Hori S, Gotoh D, Nakai Y, Miyake M, Fujimoto K.

BMC Res Notes. 2019 Feb 2;12(1):72. doi: 10.1186/s13104-019-4105-7.

18.

Expression of peptide transporter 1 has a positive correlation in protoporphyrin IX accumulation induced by 5-aminolevulinic acid with photodynamic detection of non-small cell lung cancer and metastatic brain tumor specimens originating from non-small cell lung cancer.

Omoto K, Matsuda R, Nakai Y, Tatsumi Y, Nakazawa T, Tanaka Y, Shida Y, Murakami T, Nishimura F, Nakagawa I, Motoyama Y, Nakamura M, Fujimoto K, Hiroyuki N.

Photodiagnosis Photodyn Ther. 2019 Mar;25:309-316. doi: 10.1016/j.pdpdt.2019.01.009. Epub 2019 Jan 11.

PMID:
30639584
19.

Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.

Hori S, Miyake M, Tatsumi Y, Morizawa Y, Nakai Y, Onishi S, Onishi K, Iida K, Gotoh D, Itami Y, Tanaka N, Fujimoto K.

Oncol Rep. 2019 Mar;41(3):1863-1874. doi: 10.3892/or.2019.6965. Epub 2019 Jan 10.

PMID:
30628699
20.

Preoperative predictive factors focused on inflammation-, nutrition-, and muscle-status in patients with upper urinary tract urothelial carcinoma undergoing nephroureterectomy.

Itami Y, Miyake M, Tatsumi Y, Gotoh D, Hori S, Morizawa Y, Iida K, Ohnishi K, Nakai Y, Inoue T, Anai S, Tanaka N, Shimada K, Hirao S, Fujimoto K.

Int J Clin Oncol. 2019 May;24(5):533-545. doi: 10.1007/s10147-018-01381-y. Epub 2019 Jan 2.

PMID:
30604161

Supplemental Content

Loading ...
Support Center